

Saudi Liver Meeting 2024

WorkShops
will be on Thursday
 **17** October
2024
**Princess Noura
University**
 Riyadh

Register now



28
CME
HOURS
ACCREDITED
www.saudisaslt.org.sa

TABLE of CONTENTS

Welcome Message	3
Committee	4
Conference Location	11
Agenda	12
Sponsors	23

WELCOME MESSAGE



Welcome to SLM 2024! Join us for high-quality presentations by renowned experts in hepatology. This event is not to be missed!

Welcome to the Saudi Liver Meeting 2024 (SLM) from the Saudi Society for the Study of Liver Disease and Transplantation (SASLT) and its governing board. It is with great honor that we extend our warmest greetings to all participants attending the event, which will take place from October 17 to 19, 2024

At SASLT, our mission is to advance knowledge about liver health and disease, with a particular emphasis on excellence in clinical hepatology and liver transplantation in the Kingdom of Saudi Arabia. We strive to promote research and innovation and collaborate with all stakeholders to create a society with a healthy liver.

Over the years, we have remained committed to upholding the highest standards of scientific activities, keeping pace with the rapid changes in hepatology and liver transplantation. Our goal is to elevate our scientific gatherings to international standards.

The SLM provides a platform for experts, colleagues, healthcare providers, and associates to exchange information, discuss the latest research, and explore new developments in Hepatology, and liver transplantation. It also offers an opportunity to network with leading experts in the field.

We would like to express our gratitude to the organizing and scientific committees for their unwavering support and tireless efforts in making this event possible.

Once again, we extend a sincere welcome to all participants and encourage everyone to actively participate by sharing their valuable opinions and suggestions. We hope you have an enjoyable and productive meeting over the course of the next three days.

Sincerely,

Dr. Faisal Abaalkhail

SASLT President
Saudi Society for the
Study of Liver Disease and
Transplantation

ORGANIZING COMMITTEE



Dr. Nasser AlMasri



Dr. Faisal AbaAlkhalil



Dr. Hamad AlBahili



Dr. Adel AlQutub



Mr. Thyab AlThayab



Dr. Muath Najmi



Dr. Bader AlDahash



Dr. Abdulmohsen Alshammari



Ms. Mashora Salwang



Ms. Nadeen Aqil

SCIENTIFIC COMMITTEE



Dr. Mohammed Alghamdi



Dr. Faisal AbaAlkhail



Prof. Saleh Al Qahtani



Dr. Hamad AlBahili



Dr. Mohammad Shagrani



Dr. Mohammad Mawardi



Dr. Mohammad Mawardi



Dr. Almoutaz Hashim



Dr. Waleed Alghamdi



Dr. Abdulwahed Alotay



Dr. Fahad Almalki



Dr. Hadi Kuriry



Dr. Ibrahim AlRajhi



Dr. Badr Alhumayyd



Dr. Adel AlQutub



Dr. May Alzahrani



Dr. Khalid AlHarbi



Dr. Fuad Mohammed



Dr. Hani Jawa



Dr. Abdulaziz Tashkandi



Dr. Saad Alghamdi



Dr. Muhanad AlRuwaithi



Dr. Mohammed Ayoub



Dr. Ashraf AlSahafi



Dr. Saleh Alqahtani



Dr. Ammar Khyat



Dr. Mohammad Shagrani



Dr. Ibrahim AlHasan



Dr. Ali Alyami



Dr. Abdullah Algarni



Dr. Abdullatif Musa



Mrs. Rehab Abdullah




Dr. Lolwa AlObaid



Dr. Fahad Almugbel



Dr. Mohammed Al Qahtani



Dr. Trevor Reichman



Dr. Aymen Almuhaydb



Dr. Shahid Farid

SPEAKERS



Prof. Saleh Al Qahtani



Dr. Zobair Younossi



Dr. Khalid Alswat



Dr. Muneera Altarrah



Dr. Said AlBusafi



Dr. Mohammed Alzaabi



Dr. Jawad Khamis



Dr. A.G. (Onno) Holleboom



Dr.-Nawal AlNahdi



Dr. Hirokazu Takahashi



Dr. Maria Buti



Dr. Abdullah Alghamdi

Moderators



Prof. Abdulrahman Aljumah



Prof. Hamad Alashgar



Dr. Razan Badar



Dr. Saleh Alqahtani




Dr. Sateesh Maddirevula



Prof. Mohammed AlSebayel



Dr. Hamad AlBahili



Dr. Mohammed Shaheen



Dr. Mansour Tawfeeq



Dr. Abed AlLehibi



Dr. Faisal AbaAlkhail



Prof. Saleh Al Qahtani



Dr. Faisal Sanai



Dr. Karim Qumosani



Dr. Mona Ismail



Dr. Abduljaleel Alalwan

Moderators



Dr. Hamdan Alghamdi



Dr. Mohamed Babatin



Prof. Ibrahim Altraif



**Simulation &
Skills
Development
Center**



Session		Thursday	
AM	Adult Hepatology Course	Pediatric Hepatology Course	
PM		Liver Tx Coordinator course	
Satellite Symposium + Dinner			

Session		Friday	
AM	Adult Hepatology	Poster Session	
	Pediatric Hepatology		
PM	Liver Transplance	Poster Session	
	Endo Hepatology		
Satellite Symposium + Dinner			

Session		Saturday	
AM	Adult Hepatology	The Global NASH Council Symposium	
PM		SASLT Award	
		Poster Session	

Adult Hepatology Course

Venue: Auditorium

Pre-conference (Thursday): 17 October 2024

07:30 – 08:00 AM

Registration

Dr. Mohammad Mawardi
Course Director

08:00 – 08:15 AM

Introduction

Dr. AlMoutaz Hashem

08:00 – 08:15 AM

Metabolic Dysfunction
Associated Steatotic Liver
Disease (MASLD)/
Alcoholic Related Liver
Disease (ARLD)

Question & Answer

Dr. Waleed Alghamdi

08:35 – 09:00 AM

Metabolic Liver Diseases
Wilson/Hemochromatosis
/A1AT Deficiency

Question & Answer

Dr. Abdulwahed AlOtay

09:00 – 09:30 AM

Autoimmune Liver
Disease (Autoimmune
hepatitis (AIH)/Primary
biliary cholangitis (PBC)/
Primary sclerosing
cholangitis (PSC)

Question & Answer

Dr. Fahad AlMalki

09:30 – 10:00 AM

Acute Liver Failure
/Acute on Chronic Liver
Failure

Question & Answer

Dr. Hadi Kuriry

10:00 – 10:20 AM

Drug Induced Liver
injury

Question & Answer

Dr. Ibrahim AlRajhi

10:20 – 10:40 AM

Hepatocellular
Carcinoma Approach
Management Pathway

Question & Answer

Dr. Badr Alhumayyd

10:40 – 11:00 AM

Portal Hypertension /
Variceal Gastrointestinal
Bleeding

Question & Answer

Dr. Adel AlQutub

11:00 – 11:30 AM

Hepatic Encephalopathy

Question & Answer

11:30 – 01:00 PM

Prayer & Lunch Break

Dr. May Alzahrani

01:00 – 01:20 PM

Ascites /Hepatorenal Syndrome

Question & Answer

Dr. Khalid AlHarbi

01:20 – 01:40 PM

Hepato-pulmonary Syndrome /
Porto-pulmonary hypertension

Question & Answer

Dr. Fuad Hussein

01:40 – 02:10 PM

Management of Hepatitis B Virus / Hepatitis D Virus

Question & Answer

Dr. Hani Jawa

02:10 – 02:30 PM

Nutrition in Patients with Chronic Liver Disease

Question & Answer

Dr. Abdulaziz Tashkandi

02:30 – 02:50 PM

Pregnancy Related Liver Diseases

Question & Answer

Dr. Hadeel AlManea

02:50 – 03:10 PM

Liver Pathology Slides

Question & Answer

Dr. Saad Ali Alghamdi

03:10 – 03:30 PM

Liver Transplant for Non-Transplant Hepatologist (Blue prints)

Question & Answer

Coffee Break

03:30 – 04:00 PM

Dr. Mohammad Mawardi

04:00 – 05:00 PM

Multiple Choice Question (MCQ) Panel Speaker Discussion

Closing Remarks

05:00 PM

END of POST GRADUATE COURSE

Satellite Symposium (Novo Nordisk)
Fairmont hotel

07:00 – 08:00 PM

Dinner Fairmont Hotel – Dammam AuditoriumI

08:00 – 10:00 PM

Pediatric Hepatology Course

Pre-conference (Thursday AM): 17 October 2024

07:30 – 08:00 AM

Registration

08:00 – 08:05 AM

Welcome Address

Dr. Muhanad AlRwaethi
KFMC

08:05 – 08:40 AM

Cholestasis

Question & Answer

Dr. Mohammed Ayoub
KAUH

08:45 – 09:20 AM

Approach to Elevated
Liver Enzymes

Question & Answer

09:20 – 09:25 AM

Dr. Ashraf Al Sahafi
National Guard

09:25 – 10:00 AM

Portal Hypertension and
Cirrhosis

Question & Answer

10:00 – 10:05 AM

Dr. Saleh Al Qahtani
(KFUH-Alkhubar)

10:05 – 10:45 AM

Metabolic and Genetic
Liver Disease

Question & Answer

10:45 – 10:50 AM

Dr. Ammar Khyat
KAUH

10:50 – 11:25 AM

Acute Liver Failure

Question & Answer

11:25 – 11:30 AM

Dr. Mohammed Shagrani
11:30 – 12:05 AM

Pediatric Liver Transplant

Question & Answer

12:05 – 12:10 AM

12:10 AM

Closing

The Transplant Coordinators' Workshop

Pre-conference (Thursday PM): 17 October 2024

01:30 – 02:00 PM

Registration

Dr. Ibrahim Al Hasan

02:00 – 02:20 PM

Approach to liver patients going for liver transplant

Dr. Ali Al Yami

02:20 – 02:40 PM

Approach to potential liver donors

Dr. Abdullah Al Garni

02:40 – 03:00 PM

Tips & tricks in preparing liver grafts from deceased and

Dr. Abdullatif Musa

03:00 – 03:20 PM

Ex-Vivo machine

Mrs. Rehab Abdullah

03:20 – 03:40 PM

Liver transplant work up journey; Role of the coordinator

Dr. Ibrahim Al Hasan

03:40 – 04:00 PM

Question & Answer

Dr. Ali Al Yami

04:00 PM

Closing

Saudi Liver Meeting 2024

Venue: Main Auditorium

Day 1 (Friday): 18 October 2024

07:30 – 08:00 AM

Registration

Dr. Nasser AlMasri

08:00 – 08:25 AM

Introduction by SASLT
Organizing committee

08:25 – 08:35 AM

Adult Hepatology Session (1)

Moderators: Prof. Abdulrahman AlJumah

Dr. Lolwa Alobaid

08:35 – 08:55 AM

Low Level Viremia,
which guidelines should
I adhere to?

Dr. Fahad Almugbel

08:55 – 09:15 AM

The new Therapy for
Hepatocellular Carcinoma
(HCC), immunotherapy
response in viral vs.
non-viral HCC

09:15 – 09:25 AM

Question & Answer

09:25 – 09:35 AM

Coffee Break

09:35 – 09:45 AM

opening ceremony

Pediatric Hepatology

Moderators: Dr. Razan Badar - Dr. Sateesh Maddirevula
Dr. Saleh Al Qahtani

Dr. Mohammed Ayoub

09:45 – 10:05 AM

Alagille syndrome new insight 2024
(International vs. National Data)

Dr. Ammar Khyat

10:30 – 11:10 AM

Autoimmune Liver Disease, New Modality of Treatment

Dr. Ashraf AlSahafi

10:05 – 10:25 AM

Portal Vein Thrombosis, when to interfere

11:10 – 11:20 AM

Question & Answer

Dr. Muhanad AlRwaethi

10:25 – 10:50 AM

Acute Presentation of Wilson Disease

11:20 – 11:40 AM

Pediatric Satellite Symposium for IPSEN

11:40 – 01:30 PM

Prayer & Lunch Break

01:30 – 01:50 PM

Adult Satellite Symposium for IPSEN

Liver Transplant

Moderators: Dr. Hamad Albahili - Prof. Mohammed AlSebayel
Dr. Mohammed Shaheen

Dr. Mohammed Alqahtani

01:50 – 02:10 PM

Liver transplant in the Arab countries

Dr. Abdullatif Musa

02:35 – 03:00 PM

Marginal Deceased donor grafts, the role of Ex. Vivo Machine

Dr. Trevor Riechman

02:15 – 02:35 PM

Liver transplant for Hepatocellular Carcinoma beyond Milan, what are the limits?
Toronto experience

03:00 – 03:15 PM

Question & Answer

03:15 – 03:30 PM

Coffee Break

Endo-Hepatology

Moderators: Dr. Mansour Tawfiq
Dr. Abed ALLehibi

Dr. Aymen AlMuhaidb

03:30 – 03:50 PM

Hepato Endoscopy Updates

Dr. Shahid Farid


03:50 – 04:10 PM

Biliary complication in
liver transplant, role of
biodegradable stents

END of Day 1

Satellite Symposium (New Bridge) Fairmont Hotel
07:00 – 08:00 PM

Gala Dinner - Fairmont Hotel



Global NASH Program

Day 2 (Saturday): 19 October 2024

07:30 – 08:00 AM

Registration

Prof. Saleh Alqahtani
Dr. Zobair M. Younossi

08:00 – 08:05 AM

Global Nonalcoholic Steatohepatitis
(NASH) Program

Session 1

Moderator: Dr. Faisal Abaalkhail

Nonalcoholic Fatty Liver Disease (NAFLD) in Saudi Arabia and the Gulf Region

Dr. Zobair M. Younossi

08:05 - 08:25 AM

Global Disease Burden for Nonalcoholic Fatty Liver Disease (NAFLD) and the Role of Global Nonalcoholic steatohepatitis (NASH) Council

Moderator: Prof. Saleh Alqahtani

Dr. Faisal Sanai

Regional Metabolic Dysfunction-Associated Steatotic Liver Disease Burden Highlights

Prof. Khalid Alswat

08:25 – 08:35 AM

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Burden in Saudi Arabia

Dr. Said Al-Busafi

08:45 – 08:55 AM

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Burden in Oman

Dr. Munira AlTarrah

08:35 – 08:45 AM

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Burden in Kuwait

Dr. Mohammed Alzaabi

08:55 – 09:05 AM

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Burden in UAE

Dr. Jawad Khamis
09:05 – 09:15 PM

Metabolic Dysfunction-Associated
Steatotic Liver Disease (MASLD)
Burden in Bahrain

09:15 – 09:35 AM

Question & Answer: Round Table
Discussion

09:35 – 09:50 AM

Coffee Break

Session 2

Moderator: Dr. Karim Qumosani
Dr. Mona Ismail

Noninvasive Testing (NIT) in Metabolic Dysfunction-Associated
Steatotic Liver Disease (MASLD)

Dr. A.G. (Onno) Holleboom

09:50 – 10:10 AM

Overview Noninvasive Testing
(NIT)s in Metabolic
Dysfunction-Associated Steatotic
Liver Disease (MASLD)

Dr. Nawal AlNahdi

10:10 – 10:30 AM

Optimal utilization of Noninvasive
Testing (NITs) to Identify High Risk
Metabolic Dysfunction-Associated
Steatotic Liver Disease (MASLD)

10:30 – 10:50 AM

Question & Answer: Round Table
Discussion

Session 3

Moderators: Dr. Abduljaleel Alalwan

Dr. Hamdan Alghamdi

Treatment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Dr. Hirokazu Takahashi

10:40 – 11:00 AM

Associations between liver disease and metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

11:20 – 11:35 PM

Question & Answer:
Round Table Discussion

11:35 – 01:00 PM

Prayer & Lunch Break

Prof. Saleh Alqahtani

11:00 – 11:20 AM

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) treatment - lifestyle intervention & Pharmacology

SASLT Award

01:00 – 01:20 PM

SASLT Excellence Award

01:20 – 01:40 PM

Satellite Symposium Gilead

Adult Hepatology Session (2)

Moderators: Dr. Mohammed Babbain

Prof. Ibrahim Altraif

Adult Hepatology

Dr. Maria Buti

01:40 – 02:10 PM

Hepatitis C and Hepatitis Delta virus updates

02:50 – 03:00 PM

Question & Answer

Dr. Abdullah Saeed Alghamdi

02:10 – 02:30 PM

SASLT Hepatitis C guidelines

03:00 PM

Closing

Dr. Majd Alsayb

02:30 – 02:50 PM

Cholestatic Liver Disease Updates

Platinum Sponsors



Gold Sponsor



Silver Sponsors




Bronze Sponsors



Progressive familial intrahepatic cholestasis (PFIC)

Bylvay is the first non-surgical biliary diversion treatment for all PFIC types

Bylvay is a novel, reversible, potent, selective ileal bile acid transporter (IBAT) inhibitor¹



By targeting IBAT, Bylvay:

- Blocks intestinal reabsorption of bile acid and diverts them via faecal excretion^{1,2}
- Helps reduce the bile acid pool recirculating to the liver, reducing its exposure to injury¹

Bylvay helps preserve native liver and potentially negates the need for surgical biliary diversion²⁻⁵

Progressive familial intrahepatic cholestasis (PFIC)

Redefine what is possible and rebuild lives with Bylvay¹



Helping kids to
thrive
physical and emotional wellbeing

Protecting futures
and the chance to
shine



The first non-surgical treatment for PFIC¹



Scan QR code
for SmPC



BYL-PFIC-SA-000005

1. Bylvay Summary of Product Characteristics.
2. Bedoyan SM, et al. Expert Opin Pharmacother. 2022;23:1771-79.
3. Clemson C, et al. Native liver survival in odevixibat serum bile acid responders: data from the intrahepatic cholestasis. Presented at AASLD: American Association for the Study of Liver Di
4. NICE (National Institute for Clinical Excellence) technology appraisal: Odevixibat for treating at <https://www.nice.org.uk/guidance/hst17>. Last accessed November 2022.
5. Thompson RJ, et al. Lancet Gastroenterol Hepatol. 2022;7:830-42.

For Adverse Events Reporting: Pharmacovigilance.ksa@ipsen.com

About Us

NewBridge Pharmaceuticals is a specialty company operating since 2010 across the Middle East and North Africa region. (MENA)

NewBridge" as the name suggests is focus" on Licensing New Global Innovative Therapies in the specialty space & Bridge the access gap allowing these innovations to successfully come to the MENA Patients

By doing so, we partner with Global Pharma and act as their one stop solution to MENA



CONFIDENTIAL



Novo Nordisk in MASH: clinical development and beyond

There are several barriers to effective clinical management of patients living with non-alcoholic steatohepatitis, or MASH. Novo Nordisk is committed to addressing these clinical barriers through a robust clinical development program and ongoing collaborations for biomarker research development





ACHIEVING BOLD AMBITIONS

For more than 35 years, we've been tackling some of the world's greatest public health challenges. We've revolutionized HIV treatment and prevention, delivered a cure for hepatitis C and made advancements in therapies for viral diseases and



PI



DIFFERENT QUESTIONS. SAME ANSWER.

EPCLUSA[®]

sofosbuvir / velpatasvir
400 mg / 100 mg tablets

EPCLUSA is indicated for the treatment of chronic hepatitis C virus (HCV) infections in adults. Prescribing information is available within this application. See the [DIPIC] for complete dosing information.



Reporting suspected adverse reactions of medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the National Pharmacovigilance Centre (NPC) unified number: 19999 or email: npc.drug@sfd.gov.sa. Adverse reactions may also be reported directly to Gilead. Adverse reactions related to Gilead products may be reported directly to Gilead via Safety_FC@gilead.com. SA-VEH-0040/ prepared in Oct. 2024



SASLT

الجمعية السعودية لأمراض وزراعة الكبد
Saudi Society for the Study of Liver Disease
and Transplantation



2024